Optilume药物涂层球囊治疗复发性球部尿道狭窄的五年结局:ROBUST I研究
ROBUST I研究纳入53例复发性球部尿道狭窄≤2 cm且管腔<12F的成年男性,采用Optilume药物涂层球囊治疗。5年功能性成功率为58%(25/43),无重复干预率Kaplan-Meier估计为71.7%,国际前列腺症状评分、最大尿流率和残余尿量均持续改善。
要点
- 5年功能性成功率为58%(25/43),无重复干预率Kaplan-Meier估计为71.7%。
- 国际前列腺症状评分均值从基线25.2降至5年7.2(P < .001)。
- 最大尿流率从基线5.0 mL/s改善至5年19.9 mL/s,残余尿量从141.4 mL降至59.5 mL(P < .01)。
核心结论
- 在既往内镜治疗失败的复发性球部尿道狭窄男性中,Optilume药物涂层球囊在5年时显示主观和客观排尿参数持续改善。
- 作者认为Optilume是希望避免尿道成形术的合适选择的复发性球部尿道狭窄男性的安全有效治疗选择。
研究设计与样本
- ROBUST I研究为5年研究关闭结果报告,评估Optilume药物涂层球囊对短段复发性球部尿道狭窄男性的安全性和有效性。
- 纳入标准为复发性球部尿道狭窄≤2 cm且管腔<12F的成年男性,共53例入组并接受治疗,31例完成全部随访。
主要发现
- 5年时功能性成功(国际前列腺症状评分改善≥50%且未再治疗)率为58%(25/43)。
- 国际前列腺症状评分均值从基线25.2改善至5年7.2(P < .001)。
- 无重复干预率经Kaplan-Meier估计在5年时维持于71.7%。
- 最大尿流率从基线5.0 mL/s改善至5年19.9 mL/s(P < .01),平均残余尿量从141.4 mL降至5年59.5 mL(P < .01)。
- 勃起功能未受影响,无严重治疗相关不良事件。
关键数值与推荐
- 功能性成功定义为国际前列腺症状评分改善≥50%且未再治疗。
- 纳入标准为复发性球部尿道狭窄长度≤2 cm且管腔<12F。
临床怎么用
- 作者认为Optilume是希望避免尿道成形术的合适选择的复发性球部尿道狭窄男性的安全有效治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report the 5-year study closeout results for the ROBUST I trial evaluating the safety and efficacy of the Optilume drug-coated balloon (DCB) for men with short, recurrent bulbar urethral strictures. MATERIALS AND METHODS: Adult men with recurrent bulbar urethral strictures ≤ 2 cm long and lumen < 12F were included in the study and treated with the Optilume DCB. Outcome measures included symptom questionnaires, maximum urinary flow rate, postvoid residual, and freedom from repeat intervention. Functional success was defined as improvement in International Prostate Symptom Score ≥ 50% without re-treatment. RESULTS: Fifty-three men were enrolled and treated, and 31 subjects completed all follow-up. Functional success was achieved in 58% (25/43) patients at 5 years. Average International Prostate Symptom Score improved from a mean of 25.2 at baseline to 7.2 at 5 years (P < .001). Freedom from repeat intervention was maintained through 5 years at 71.7% estimated by Kaplan-Meier. Maximum urinary flow rate improved from 5.0 mL/s at baseline to 19.9 (P < .01), and average postvoid residual was reduced from 141.4 mL to 59.5 mL (P < .01) at 5 years of follow-up. Erectile function remained unaffected. There were no serious treatment-related adverse events. CONCLUSIONS: In this challenging cohort of men with failed prior endoscopic treatment, the Optilume DCB shows sustained improvement in subjective and objective voiding parameters at 5 years. Optilume is a safe and effective treatment option for appropriately selected men with recurrent bulbar urethral stricture who wish to avoid urethroplasty. Results are in line with the ROBUST III randomized controlled trial that will continue follow-up through 5 years.
引用
- DeLong J, Virasoro R, Pichardo M, et al. Long-Term Outcomes of Recurrent Bulbar Urethral Stricture Treatment With the Optilume Drug-Coated Balloon: Five-Year Results From the ROBUST I Study. J Urol. 2024. PMID: 39213367. doi:10.1097/JU.0000000000004229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。